1.888.443.3311

Web Site Search

ABOUT US

TEST MENU

ORDERING

CAREERS

EVENTS

YOUR ACCOUNT

PATIENT HEALTH

Mammostrat - Breast Cancer Treatment

Clarient InsightDx^® Mammostrat^®

Mammostrat is a novel test for estimating the risk for recurrence in hormone-receptor positive, early stage breast cancer that is independent of proliferation and grade. Five biomarkers are combined with a defined mathematical algorithm resulting in a risk index. Mammostrat is clinically validated and has been studied on more than 4,500 total patients in numerous independent cohorts that include the NSABP B14 and B20 trials.

To learn more about Mammostrat, please visit our Clarient booth at one of the following events.

National Comprehensive Cancer Network

Miami Breast Cancer Conference

US & Canadian Academy of Pathology

American Society - Breast Surgeons

American Society of Clinical Oncology

College of American Pathologists

San Antonio Breast Cancer Symposium

View all events details

Why Mammostrat?
Drs. Ken Bloom & Doug Ross Discuss

Overview

Ken J. Bloom, MD, FCAP

Douglas T. Ross, MD, PhD

Development

Validation

Differences - Dr. Bloom

Differences - Dr. Ross

Benefits - Dr. Bloom

Benefits - Dr. Ross

Clinicians

Mammostrat, a highly validated breast panel, provides clinicians a risk of recurrence assessment, independent of proliferation and grade, at the time of hormonal status (within 48-72 hours), to help better guide treatment decisions.

Learn more about Mammostrat.

Patients

Mammostrat is a test for early stage breast cancer patients whose tumor has been diagnosed as “estrogen receptor positive."

Learn more about the Mammostrat assay or about your Mammostrat report.